Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-24
2006-10-24
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S414000, C548S505000
Reexamination Certificate
active
07125906
ABSTRACT:
The invention relates to the use of a compound of Formula (I), for the manufacture of a medicament to inhibit and/or reverse and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis:wherein: X, p, q, R1, R2, R3, R4, and R5are as defined in the description. The invention also related to use of compounds of Formula (I) as medicaments and also to novel compounds of Formula (I). The invention further provides pharmaceutical compositions of compounds of Formula (I) and processes for the synthesis of compounds of Formula (I).
REFERENCES:
patent: 2789984 (1957-04-01), Speeter
patent: 2802003 (1957-08-01), Grogan et al.
patent: 2849454 (1958-08-01), Szmuszkovicz
patent: 2883394 (1959-04-01), Schindler
patent: 2890223 (1959-06-01), Woolley et al.
patent: 2984670 (1961-05-01), Szmuszkovicz et al.
patent: 2991291 (1961-07-01), Szmuszkovicz
patent: 3037031 (1962-05-01), Lewis
patent: 3166570 (1965-01-01), Winthrop
patent: 3168526 (1965-02-01), Heinzelman et al.
patent: 3901914 (1975-08-01), Hannah
patent: 4533672 (1985-08-01), Eakin et al.
patent: 4952584 (1990-08-01), Thompson et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 380129 (1964-09-01), None
patent: 402860 (1966-05-01), None
patent: 414639 (1966-12-01), None
patent: 0107963 (1987-04-01), None
patent: 0393575 (1994-03-01), None
patent: 0372962 (1994-07-01), None
patent: 0708091 (1996-04-01), None
patent: 1297833 (2003-04-01), None
patent: 227606 (1957-03-01), None
patent: 1238756 (1960-02-01), None
patent: 1388973 (1965-02-01), None
patent: 770370 (1957-03-01), None
patent: 807620 (1959-01-01), None
patent: 832855 (1960-04-01), None
patent: 834028 (1960-05-01), None
patent: 839628 (1960-06-01), None
patent: 841524 (1960-07-01), None
patent: 869775 (1961-06-01), None
patent: 873777 (1961-07-01), None
patent: 886684 (1962-01-01), None
patent: 942548 (1963-11-01), None
patent: 1033253 (1966-06-01), None
patent: 200080295 (2000-03-01), None
patent: 175967 (1965-10-01), None
patent: WO 94/14770 (1994-07-01), None
patent: WO 98/39323 (1998-09-01), None
patent: WO 99/12905 (1999-03-01), None
patent: WO 99/29660 (1999-06-01), None
patent: WO 99/29661 (1999-06-01), None
patent: WO 99/51598 (1999-10-01), None
patent: WO 99/51600 (1999-10-01), None
patent: WO 00/48606 (2000-08-01), None
patent: WO 00/66585 (2000-11-01), None
patent: WO 01/19794 (2001-03-01), None
patent: WO 01/29025 (2001-04-01), None
patent: WO 01/82909 (2001-11-01), None
patent: WO 200182909 (2001-11-01), None
patent: WO 01/92224 (2001-12-01), None
patent: WO 02/70478 (2002-09-01), None
Sheppard, G, S. ‘3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists’Journal Of Medicinal Chemistryvol. 37, No. 13, 2011-2032, 1994.
Kwong, F, Y & Buchwald, S. L. ‘A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiois’Org. Lett. vol. 4, No. 20, 3517-3520, 2002.
Database Crossfire Beilstein ‘Beilstein institute zur foerdering der chemischen wissenschaften’ Database Accession No. 8172403, 2000.
Database Crossfire Beilstein ‘Beilstein institute zur foerdering der chemischen wissenschaften’ Database Accession No. 183150, reaction 2 of 4, 1988.
Database Crossfire Beilstein ‘Beilstein institute zur foerdering der chemischen wissenschaften’ Database Accession No. 5433848, 1993.
Monge A et al ‘New indole and pyridazinoindole analogs—synthesis and study as inhibitors of phosphodiesterases and as inhibitors of blood platelet aggregation’Archiv Der Pharmazievol. 328, No. 10, pp. 689-698, 1995.
Aleksandrzak, K. McGown, A, T & Hadfield, J, A. ‘Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4’Anti-Cancer Drugsvol. 9, 545-550, 1998.
McGown, A, T. & Fox, B, W. ‘Structural and biochemical comparison of the anti-mitotic agents colchicines, combretastatin A4 and amphethinile’Anti-Cancer Drug Designvol. 3, pp. 249-254, 1989.
Galbraith, S. M et al. ‘Effects of combrestatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo’Anti-Cancer Researchvol. 21, pp. 93-102, 2001.
Bolton, D et al ‘Synthesis and potential anxiolytic activity of 4-amino-pyrido[2,3-b]indoles’Bioorganic&Medicinal Chemistry Lettersvol. 3, No. 10, pp. 1941-1946, 1993.
Blackburn, T,P. ‘11-amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, a novel GABAAmodulator with Potential anxiolytic activity’Bioorganic&Medicinal Chemistry Lettersvol. 4, No. 2, pp. 279-284, 1994.
McGown, A, T et al. ‘Pre-clinical studies of a novel anti-mitotic agent, amphethinile’Br J Cancervol. 57, pp. 157-159, 1988.
McGown, A, T. & Fox, B, W. ‘Interaction of the novel agent amphethinile with tubulin’Br J Cancervol. 59, pp. 865-868, 1989.
Newell, D, R et al ‘Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics’British Journal of Cancervol. 81(5), pp. 760-768, 1999.
Dark, G, G. ‘Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vascilature’Cancer Researchvol. 57, pp. 1829-1834, 1997.
Player, M, R & Sowell, J, W. ‘Synthesis of 1,3-disubstituted-2-amino-5-hydroxyindoles by reductive aromatization’J Heterocyclic Chemvol. 30 (125), pp. 125-128, 1993.
Hess, S et al. ‘7-deazaadenines bearing polar substituents: structure-activity relationships of a new A1and A3adenosine receptor antagonists’J Med Chem′vol. 43, pp. 4636-4646, 2000.
Fuse, E et al. ‘Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity’Journal of the National Cancer Institutevol. 86, No. 13, 1994.
Eger, K et al ‘Synthesis of substituted indoles and pyrimido[4,5-b]indoles by dehydration of tetrahydroindoles and tetrahydropyrimidoindoles’Liebigs Ann Chempp. 465-470, 1993.
Keglevic, D & Goles, D ‘Indole compounds. VI. Syntheses of indole thioethers by direct cyclization of phenylhydrazine hydrochlorides and aliphatic acetals under mild conditions’Croatica Chemica Actavol. 42, pp. 513-521, 1970.
Desaty, D et al ‘The synthesis of N-acetylserotonin’Biochem Biophys Actavol. 62, pp. 179-180, 1962.
Mashima, H & Matsumura, M. ‘Roles of external ions in the excitation-contraction coupling of frog skeletal muscle’Japan J. Physiolvol. 12, pp 639-653, 1962.
Heath-Brown, B & Philpott, P. G. ‘Studies in the indole series. Part 1. Indolylalkylamines’J Chem Socpp. 7165-7078, 1965.
Desai, H. K. & Usgaonkar, R, N. ‘Isocoumarins. Part 1. Synthesis of 4-Methylisocoumarins’Jour Indian Chem Socvol. 41, No. 12, pp. 821-829, 1964.
Heacock, R, A. & Hutzinger, O. ‘The preparation of the hydroxyskatoles and 5,6-dihydroxyskatole’Canadian Journal of Chemistryvol. 42, pp. 514-521, 1964.
Ma, J, C, N & Warnhoff, E, W. ‘On the use of nuclear magnetic resonance for the detection, estimation and characterization of N-methyl groups’Canadian Journal of Chemistryvol. 43, pp. 1849-1869, 1965.
Benigni, J, D & Minnis, R, L. ‘The synthesis of 5,6-dihydroxyindole and some of its derivatives (1)’J Heterocyclic Chemvol. 2, pp. 387-392, 1965.
Marchand, B et al ‘Preparative chemistry of indole compounds. 1. Preparation of phenylhydrazones of pyruvic acid esters from methyloxalacetic esters and diazonium salts and conversion of these compounds into indole-2-carboxylic esters’J Prakt Chemvol. 13, pp. 54-57, 1961. +English Abstract.
Taborsky, R, G. & Delvigs, P. ‘Synthesis of some substituted tryptophols of possible physiological importance and a study with 3-(2-acetoxyethyl)-5-methoxyindole (5-methoxytryptophol O-acetate) on sexual maturation’J Med Chemvol. 9, pp. 251-254, 1966.
Taborsky, R, G e
AstraZeneca AB
Grazier Nyeemah
LandOfFree
Indole derivatives having anti-angiogenetic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole derivatives having anti-angiogenetic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole derivatives having anti-angiogenetic activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718809